Insurance Policies Delayed Cancer Treatment Access
A September 2026 report highlighted how utilization management and gaps in biomarker testing restrict patient care.
Updated on Oct. 10, 2026 in Cancer
Live Poll
Do you trust that insurance policies prioritize patient health outcomes over administrative or cost-saving measures?
A September 2026 report found that administrative hurdles, including restrictive insurance policies, frequently impede access to recommended chronic lymphocytic leukemia (CLL) treatments. Research indicated that these policies often override clinical evidence in determining patient access.
Why it matters
Restrictive insurance utilization management policies prevent patients from utilizing innovative therapies that have pushed 5-year survival rates for CLL to nearly 90%. Inconsistent access to necessary biomarker testing further complicates the delivery of precision oncology care.
Oncologists reported 97% of insurers interfere with care, while 91% state policies are misaligned with clinical standards. Biomarker testing coverage is currently mandated in only 19 states as of July 2026.
The players
Charles River Associates
This global consulting firm provides economic and financial analysis used by corporations and policy-making entities.
FDA
The Food and Drug Administration is the federal agency responsible for regulating medications and medical devices in the United States.
The details
Insurers frequently employ prior authorization and step therapy to delay access to prescribed medications. These administrative barriers remain a significant hurdle for patients, whose median age at diagnosis is 70 to 72 years, despite the availability of effective new FDA-approved treatments like pirtobrutinib.
Timeline
2013: The FDA approved the first BTK inhibitor for clinical use.
2016: The FDA approved the first B-cell lymphoma 2 inhibitor.
July 2026: 19 states required biomarker testing coverage.
September 2026: The Charles River Associates report was published.
October 2, 2026: The FDA approved pirtobrutinib for chronic lymphocytic leukemia.
The Big Picture
The report advocates for the adoption of the Safe Step Act to provide a standardized exception process for patients facing insurance-mandated step therapy barriers.
Patients may face significant administrative delays when seeking treatment as insurance designs prioritize utilization management over clinical guidelines. Families should be aware that 26 states currently limit copay accumulator programs, which can impact out-of-pocket costs.
The takeaway
Patients and caregivers are encouraged to work closely with oncology pharmacists to navigate complex insurance authorization processes. Understanding state-level protections regarding biomarker testing and copay accumulators can help mitigate some financial and logistical barriers to care.
Further reading
Learn more about the challenges of treatment delivery and current research in the United States Cancer section.
More information
View the complete report on CLL care gaps for further details on these findings.
Live Poll
Do you trust that insurance policies prioritize patient health outcomes over administrative or cost-saving measures?
